mTOR Inhibition for Cancer Therapy: Past, Present and Future - Softcover

Softcover

ISBN 10: 2817805577 ISBN 13: 9782817805573

Verlag: Springer, 2016

Inhaltsangabe

This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. 

Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compoundscurrently under evaluation.

Über diesen Titel

Über die Autorin bzw. den Autor

Monica Mita and Alain Mita are Associate Professors of Medicine and Co-Directors of the Experimental Therapeutics Program at the Samuel Oschin Comprehensive Cancer institute, Cedars-Sinai Medical Center in Los Angeles, CA. Eric Rowinsky is Chief Medical Officer, Head of Research and Development, and Executive Vice President at Stemline Therapeutics, Inc. He is also an Adjunct Professor of Medicine at New York University School of Medicine and a cancer drug development consultant at Oncodrugs.

Von der hinteren Coverseite

This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. 

Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation.

Details zur Ausgabe

• Verlag: Springer
• Erscheinungsdatum: 2016
• Sprache: Englisch
• ISBN 10: 2817805577
• ISBN 13: 9782817805573
• Einband: Taschenbuch
• Anzahl der Seiten: 308
• Herausgeber: Mita Monica, Mita Alain, Rowinsky Eric K.
• Kontakt zum Hersteller: Springer Nature Customer Service Center GmbH; ProductSafety@springernature.com; ; Europaplatz 3; Heidelberg; 69115; Deutschland